Aqueous Humor Cytokine Profiling Reveals Distinct Roles for Serum Amyloid A, Interleukin-8, and Endothelin-1 in Pseudoexfoliation Syndrome and Glaucoma

被引：0
作者：
Kadoh, Yoichi [1 ]
Takayanagi, Yuji [1 ]
Sugihara, Kazunobu [1 ]
Kaidzu, Sachiko [1 ]
Takai, Yasuyuki [1 ]
Tanito, Masaki [1 ]
机构：
[1] Shimane Univ, Fac Med, Dept Ophthalmol, Izumo 6938501, Japan
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2025年 / 26卷 / 04期
关键词：
pseudoexfoliation syndrome; glaucoma; exfoliation glaucoma; inflammatory cytokines; aqueous humor; Serum Amyloid A (SAA); Interleukin-8 (IL-8); Endothelin-1 (ET-1); Vascular Endothelial Growth Factor (VEGF); NORMAL-TENSION; NITRIC-OXIDE; STRESS; RISK;
D O I：
10.3390/ijms26041461
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Pseudoexfoliation syndrome (PE), which is often unilateral in 60% of cases, is a risk for exfoliation glaucoma (EXG) with elevated inflammatory cytokines. This study aimed to clarify the dynamics of these cytokines in unilateral PE (u-PE) patients. This study included 20 eyes from 10 u-PE patients (PE+ eyes and fellow PE- eyes) and 20 eyes from 10 cataract patients without PE (control group). Clinical parameters, including age, visual acuity, and intraocular pressure, were assessed. Anterior chamber aqueous humor cytokine levels (IL-8, SAA, ET-1, VEGF) were measured and compared among groups. SAA was elevated in PE+ eyes compared to PE- and control eyes. IL-8 and ET-1 were elevated in both PE+ and PE- eyes compared to controls. IL-8 was associated with worsening visual acuity, while ET-1 correlated inversely. Our findings suggest that SAA is associated with the manifest disease while IL-8 and ET-1 could be early biomarkers for PE and therapeutic targets to prevent glaucomatous damage, as these markers appear in the aqueous humor even before pseudoexfoliation material becomes clinically evident. These results may enable earlier diagnosis and therapeutic intervention before the clinical onset of PE in patients with risk factors.
引用
收藏
页数：10
相关论文
共 32 条
  • [1] Bourne R.R.A., Jonas J.B., Bron A.M., Cicinelli M.V., Das A., Flaxman S.R., Friedman D.S., Keeffe J.E., Kempen J.H., Leasher J., Et al., Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: Magnitude, temporal trends and projections, Br. J. Ophthalmol, 102, pp. 575-585, (2018)
  • [2] Ahrlich K.G., De Moraes C.G., Teng C.C., Prata T.S., Tello C., Ritch R., Liebmann J.M., Visual field progression differences between normal-tension and exfoliative high-tension glaucoma, Investig. Ophthalmol. Vis. Sci, 51, pp. 1458-1463, (2010)
  • [3] Grodum K., Heijl A., Bengtsson B., Risk of glaucoma in ocular hypertension with and without pseudoexfoliation, Ophthalmology, 112, pp. 386-390, (2005)
  • [4] Naumann G.O., Schlotzer-Schrehardt U., Kuchle M., Pseudoexfoliation syndrome for the comprehensive ophthalmologist. Intraocular and systemic manifestations, Ophthalmology, 105, pp. 951-968, (1998)
  • [5] Schlotzer-Schrehardt U., Naumann G.O., Ocular and systemic pseudoexfoliation syndrome, Am. J. Ophthalmol, 141, pp. 921-937, (2006)
  • [6] Siordia J.A., Franco J., Golden T.R., Dar B., Ocular Pseudoexfoliation Syndrome Linkage to Cardiovascular Disease, Curr. Cardiol. Rep, 18, (2016)
  • [7] Ozaki M., Mechanisms of Glaucoma in Exfoliation Syndrome, J. Glaucoma, 27, pp. S83-S86, (2018)
  • [8] Schlotzer-Schrehardt U., Khor C.C., Pseudoexfoliation syndrome and glaucoma: From genes to disease mechanisms, Curr. Opin. Ophthalmol, 32, pp. 118-128, (2021)
  • [9] Jeng S.M., Karger R.A., Hodge D.O., Burke J.P., Johnson D.H., Good M.S., The risk of glaucoma in pseudoexfoliation syndrome, J. Glaucoma, 16, pp. 117-121, (2007)
  • [10] Parekh P., Green W.R., Stark W.J., Akpek E.K., Electron microscopic investigation of the lens capsule and conjunctival tissues in individuals with clinically unilateral pseudoexfoliation syndrome, Ophthalmology, 115, pp. 614-619.e2, (2008)
1234